Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 11/04/20

Helen X. Chen, MD

Helen X. Chen, MD

Associate Branch Chief, IDB

Dr. Helen Chen joined the Cancer Therapy Evaluation Program (CTEP) of National Cancer Institute (NCI) in 2000. She currently serves as Associate Chief of the Investigational Drug Branch (IDB) Section III, which focuses on the clinical development of antibody-based therapeutics, active immunotherapies, MAPK and RTK inhibitors as well as antiangiogenic agents. She has also been closely involved in NCI’s efforts on novel agent combinations and is member of the NCI Experimental Therapeutics Committee.

Dr. Chen graduated from the Shanghai First Medical College of the Fudan University in China. She is board-certified in Medical Oncology after completing the Fellowship Training at Georgetown University Medical Center, Washington D.C. Dr. Chen also serves on external scientific committees including the International Symposium of Anti-angiogenic Therapies and Immunotherapy and the FDA-ASCO-AACR-sponsored Accelerating Anticancer Agent Development and Validation Workshop. She has presented at national and international meetings on strategies of combining novel and targeted agents, early drug development as well as antibody-based therapeutics and antiangiogenic therapies. She is the first or coauthor of over 50 original and review papers in peer-reviewed journals including Journal of Clinical Oncology, Nature Reviews, and New England Journal of Medicine.

Contact Information:
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850
Phone: 240-276-6565
Fax: 240-276-7894

About the Acting Branch Chief

Steven Gore, MD Steven Gore, MD, earned his undergraduate and doctoral degrees at Yale, performed his residency at the University of Chicago and his oncology fellowship at Johns Hopkins. He rose from instructor to full professor at Johns Hopkins, and, in 2013, he became professor of medicine and director of hematologic malignancies at Yale. He joined the Investigational Drug Branch at CTEP in 2020. More…